REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

1. REPORT DATE	2. REPORT TYPE	3. DATES COVERED
October 2015	Final Report	26Sep2011 - 25Sep2015

4. TITLE AND SUBTITLE
Molecular Imaging and Therapy of Prostate Cancer

5a. CONTRACT NUMBER
W81XWH-11-1-0644

5b. GRANT NUMBER

5c. PROGRAM ELEMENT NUMBER

6. AUTHOR(S)

Weibo Cai

E-Mail: wcai@uwhealth.org

5d. PROJECT NUMBER

5e. TASK NUMBER

5f. WORK UNIT NUMBER

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)

University of Wisconsin-Madison
21 N. Park Street, Suite 6401
Madison, WI 53715-1218

8. PERFORMING ORGANIZATION REPORT NUMBER

9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)

U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

10. SPONSOR/MONITOR'S ACRONYM(S)

11. SPONSOR/MONITOR'S REPORT NUMBER(S)

12. DISTRIBUTION / AVAILABILITY STATEMENT

Approved for Public Release; Distribution Unlimited

13. SUPPLEMENTARY NOTES

14. ABSTRACT

Our objective is to develop an arsenic-based radiopharmaceutical platform for IGF1R-targeted imaging and therapy of PCa. The hypothesis is that arsenic-based, IGF1R-targeted radiopharmaceuticals can allow for PET imaging, IRT, and monitoring the therapeutic response of PCa.

Specific Aims:
Aim 1: To optimize the production of arsenic isotopes and develop/perfect the labeling chemistry.
Aim 2: To quantitatively measure IGF1R expression in PCa models with PET imaging.
Aim 3: To monitor the efficacy of 76As-based IRT of PCa with multimodality imaging.

15. SUBJECT TERMS
Nothing Listed

16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
					USAMRMC
a. REPORT	b. ABSTRACT	c. THIS PAGE			19b. TELEPHONE NUMBER *(include area code)*
Unclassified	Unclassified	Unclassified	Unclassified	1074	

Standard Form 298 (Rev. 8-98)
Prescribed by ANSI Std. Z39.18